Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-39

First 39 Last

Share
Profile

Follow
maurico

513 Posts.

7

18/04/18

22:20

Post #: 32540836
Share

Originally posted by madamswer ↑

@maurico,

I posted the the comments, italicised below, to another poster some time back.

I feel it also serves as a relevant response to your continued criticism of me in person, rather than of what I post:

"And yet again, commentary from a MSB cheerleader that involves nothing other than speculation about my motives.

Instead of the same, laboured routine of speculating inconclusively about what the reasons behind my posting might be, why don't you display some originality for a change and make some reference to whether or not what I have posted over time contains any factual veracity, or has been proven to be accurate, or otherwise?

For example, on which of the following salient points regarding MSB is what I have posted proven to be bunkum, or even vaguely wrong?

- the company's underfunded position posing a fundamental risk to the share price;
- Teva appearing to be an unwilling and unsuitable partner for MSB;
- the NASDAQ listing being poorly structured, and unlikely to be a panacea to MSB's funding challenges;
- the extension of the right of refusal to Celgene for zero consideration not being the good sign that some were proclaiming;
- the creation of the role of vice chairman being really irrelevant when it came to improved scope for securing partners (when others were saying that it was);
- Mallinkrodt not being in any position to be a meaningful financial contributor to MSB;
- Kentgrove not being all that it was cracked up to be (heck, there were many people on this forum applauding the Kentgrove announcement, but who had zero idea of how the Kentgrove facility would even work... and there some that still don't know to this day);
- MSB's share register not represented overwhelmingly by a mere small number of large institutional investors;
- the debt arrangements with Hercules to cost a lot more than the coupon rate quoted, and that there is not enough information made public about some very relevant terms and conditions of that debt.
etc.
etc.

So, feel free to point out where the posts that I have made have been plain wrong or misleading.

(After all, as you say, there are thousands from which to choose; statistically you should be able to find a number of them that are flawed).

The previous correspondent to whom I addressed that post never came back to me with any riposte to those points of concern that I have raised over time.

Maybe you will.

Expand

I just read the first line of your essay and it is insulting for you to say that anyone with a positive view on MSB is a cheerleader. I find it ironic that you criticize MSB for repeting old news according to you. For the record, your essays are nothing more than the same rehashed broken record, don’t you have any new material to write about?

Last edited by maurico: 18/04/18

MSB Price at posting: $1.56 Sentiment: Buy Disclosure: Held
14 Upvote

3 Great analysis

Reply

Top Stories

LISTEN: HotCopper Wire Podcast #052 – A big, juicy gold megamerger

Australian resource exploration spending a 'mixed bag' on back of Middle East crisis

KAO

High-grade copper & tungsten results strengthen Karibib opportunity

LISTEN: HotCopper's Penny Drop Podcast #1 – Uranium deals, PFS misses, & an Ebola opportunity

Expert Exchange: Gold's record run (and a look at key risks) with David Sokulsky

First 39 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $2.57		Change -0.205(7.40%)		Mkt cap ! $3.589B

Open	High	Low	Volume
$2.61	$2.66	$2.55	1.825M

Buyers (Bids)

Vol.	Price($)
33288	$2.56

Sellers (Offers)

Price($)	Vol.
$2.57	17386

Last trade - 10.52am 17/07/2026 (20 minute delay)

MSB (ASX) Chart

Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-39

LISTEN: HotCopper Wire Podcast #052 – A big, juicy gold megamerger

Australian resource exploration spending a 'mixed bag' on back of Middle East crisis

High-grade copper & tungsten results strengthen Karibib opportunity

LISTEN: HotCopper's Penny Drop Podcast #1 – Uranium deals, PFS misses, & an Ebola opportunity

Expert Exchange: Gold's record run (and a look at key risks) with David Sokulsky

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-39

Top Stories

LISTEN: HotCopper Wire Podcast #052 – A big, juicy gold megamerger

Australian resource exploration spending a 'mixed bag' on back of Middle East crisis

High-grade copper & tungsten results strengthen Karibib opportunity

LISTEN: HotCopper's Penny Drop Podcast #1 – Uranium deals, PFS misses, & an Ebola opportunity

Expert Exchange: Gold's record run (and a look at key risks) with David Sokulsky

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News